文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

非中和性人源化抗肾上腺髓质素单抗Adrecizumab对猪二次打击模型血流动力学与肾损伤的影响

Effects of the Non-Neutralizing Humanized Monoclonal Anti-Adrenomedullin Antibody Adrecizumab on Hemodynamic and Renal Injury in a Porcine Two-Hit Model.
PubMed 文献 · Shock · 2020-01-01
一句话结论在猪失血性休克后脓毒症二次打击模型中,Adrecizumab 2 mg/kg 显著减少复苏液量、降低脓毒性休克发生并减少肾粒细胞浸润;作者认为该药可能对脓毒症有益,需临床研究。

研究为随机、盲法猪二次打击模型:12头德国长白猪先失血至平均动脉压降至基线一半并维持45分钟,失血性休克后6小时腹腔置入大肠埃希菌血凝块诱导脓毒症,随后随机给予Adrecizumab 2 mg/kg体重或溶媒。给药4小时后开始复苏,用平衡晶体液和去甲肾上腺素维持中心静脉压8至12 mmHg、平均动脉压≥65 mmHg、ScvO2≥70%,持续8小时。结果显示抗体组复苏液量显著更少、发生脓毒性休克动物显著更少,肾皮质与髓质粒细胞显著减少,其余4项肾脏指标未达统计学显著。作者结论为该药可能对脓毒症有益,值得开展临床研究。

要点

  • 猪二次打击模型(失血性休克后6小时腹腔大肠埃希菌血凝块)中,Adrecizumab 2 mg/kg体重组较溶媒组复苏液量显著更少、发生脓毒性休克动物显著更少
  • 抗体组肾组织学皮质与髓质粒细胞显著低于溶媒组;血清肌酐、尿量及皮质与髓质组织病理损伤4项未达统计学显著
  • 脓毒症诱导后两组血浆肾上腺髓质素均立即升高,抗体组升高更快、更明显
  • 作者结论:Adrecizumab 可能对脓毒症有益,需开展临床研究

适用人群与场景

  • 猪二次打击模型:12头德国长白猪,先失血性休克(放血至平均动脉压为基线一半,持续45分钟),6小时后腹腔置入大肠埃希菌血凝块诱导脓毒症

处置流程与药物剂量

  • 脓毒症诱导后立即给予Adrecizumab 2 mg/kg体重或溶媒溶液
  • 给药4小时后开始复苏:使用平衡晶体液和去甲肾上腺素,维持中心静脉压8至12 mmHg、平均动脉压≥65 mmHg、ScvO2≥70%,持续8小时

研究设计与关键结果

  • 随机、盲法猪二次打击模型,12头德国长白猪,比较Adrecizumab 2 mg/kg体重与溶媒溶液
  • 抗体组复苏液量显著低于溶媒组,发生脓毒性休克动物显著少于溶媒组
  • 肾组织学:抗体组皮质与髓质粒细胞显著低于溶媒组;血清肌酐、尿量、皮质与髓质组织病理损伤4项未达统计学显著
  • 脓毒症诱导后两组血浆肾上腺髓质素均立即升高,抗体组升高更快、更明显

证据类型、等级与局限

  • 证据类型:随机、盲法动物实验(猪二次打击模型)
  • 作者结论:Adrecizumab 可能对脓毒症有益,需开展临床研究
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为Adrecizumab可能对脓毒症有益,需开展临床研究;本结果为动物模型证据,未给出临床用药推荐

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Adrenomedullin is a vasoactive peptide that improves endothelial barrier function in sepsis, but may also cause hypotension and organ failure. Treatment with a non-neutralizing monoclonal anti-adrenomedullin antibody showed improvement in murine sepsis models. We tested the effects of the humanized monoclonal anti-adrenomedullin antibody Adrecizumab in a porcine two-hit model of hemorrhagic and septic shock.In this randomized, blinded study 12 German Landrace pigs were bled to half of baseline mean arterial pressure for 45 min. Sepsis was induced using an Escherichia coli clot placed into the abdominal cavity 6 h after hemorrhagic shock. Animals received either 2 mg/kg BW anti-adrenomedullin antibody or vehicle solution immediately after sepsis induction. After 4 h, resuscitation was initiated using balanced crystalloids and noradrenalin to maintain a central venous pressure of 8 to 12 mm Hg, a mean arterial pressure ≥ 65 mm Hg, and a ScvO2 ≥70% for another 8 h. Hemodynamic parameters, laboratory parameters, and kidney histology were assessed.The amount of volume resuscitation was significantly lower and significantly less animals developed a septic shock in the antibody-treated group, compared with the vehicle group. Kidney histology showed significantly lower granulocytes in both cortex and medulla in antibody-treated animals, while the remaining four kidney measures (serum creatinine and urine output and cortical and medullary injury in histopathology) did not reach the significance levels. After induction of sepsis, plasma adrenomedullin increased immediately in both the groups, but increased quicker and more pronounced in the antibody group.In this two-hit shock model, treatment with an anti-adrenomedullin antibody significantly increased plasma adrenomedullin levels, while significantly less animals developed septic shock and renal granulocyte extravasation was significantly reduced. Thus, therapy with Adrecizumab may provide benefit in sepsis, and clinical investigation of this drug candidate is warranted.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Thiele C, Simon TP, Szymanski J, et al. Effects of the Non-Neutralizing Humanized Monoclonal Anti-Adrenomedullin Antibody Adrecizumab on Hemodynamic and Renal Injury in a Porcine Two-Hit Model. Shock. 2020. PMID: 32554994. doi:10.1097/SHK.0000000000001587

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。